<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id>
<journal-title-group>
<journal-title>Dialogues in Clinical Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1294-8322</issn>
<issn pub-type="epub">1958-5969</issn>
<publisher>
<publisher-name>Les Laboratoires Servier</publisher-name>
<publisher-loc>France</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31636490</article-id>
<article-id pub-id-type="pmc">6787539</article-id>
<article-id pub-id-type="doi">10.31887/DCNS.2019.21.2/nsurana</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Harnessing the microbiota to treat neurological
diseases </article-title>
<trans-title-group xml:lang="es">
<trans-title>Aprovechamiento de la microbiota para el tratamiento de enfermedades neurológicas</trans-title>
</trans-title-group>
<trans-title-group xml:lang="fr">
<trans-title>Maîtriser le microbiote pour soigner les maladies neurologiques</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Surana</surname>
<given-names>Neeraj K.</given-names>
</name>
<degrees>MD</degrees>
<aff>Departments of Pediatrics, Molecular Genetics, Microbiology
and Immunology, Duke University, Durham, North Carolina, USA.</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="COR1">Department of Pediatrics, Duke University, 207 Research Drive, Jones
Building, Room 436, Durham, NC 27710, USA.<label>*</label> E-mail:
<email>neil.surana@duke.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<issue>2</issue>
<fpage>159</fpage>
<lpage>165</lpage>
<permissions>
<copyright-statement>© 2019, AICH – Servier Group﻿Copyright © 2019 AICH – Servier Group.
All rights reserved</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Studies over the last decade have transformed our previously simplistic view of
microbes, having only a pathogenic role in disease to a more robust understanding
that they are critical for maintaining human health. Indeed, our microbiota—the
collection of commensal organisms that live in and on each of us—contributes to
nearly every facet of host physiology, from ontogeny of the immune system to
neurological function to metabolism. Although the specific details of these
host–microbe interactions are still being elucidated for most diseases, the coupling
of clinical samples with animal models of disease have provided key insights. This
review provides some general background on the microbiota, highlights a few examples
of how the microbiota influences diseases of the central nervous system, and provides
a perspective for how these findings may be clinically translatable. </p>
</abstract>
<trans-abstract xml:lang="es">
<p>Los estudios realizados durante la última década han transformado nuestra visión previamente simplista de los microbios, en que tenían sólo un papel patogénico en la enfermedad, a una comprensión más sólida de que son claves para el mantenimiento de la salud humana. De hecho, nuestra microbiota, la colección de organismos comensales que viven en cada uno de nosotros, contribuye a casi todas las facetas de la fisiología del huésped, desde la ontogenia del sistema inmunitario hasta la función neurológica y el metabolismo. Aunque los detalles específicos de estas interacciones entre el huésped y los microbios aún se están dilucidando en la mayoría de las enfermedades, el pareo de muestras clínicas con modelos animales de enfermedades ha proporcionado información clave. Esta revisión proporciona algunos antecedentes generales sobre la microbiota, destaca algunos ejemplos de cómo ésta influye en las enfermedades del sistema nervioso central y proporciona una perspectiva de cómo estos hallazgos se pueden traducir clínicamente.</p>
</trans-abstract>
<trans-abstract xml:lang="fr">
<p>Durant la dernière décennie, des études ont transformé notre vue simpliste des microbes, ceux-ci n’ayant par le passé à nos yeux qu’un rôle pathogène dans les maladies, en une compréhension plus exhaustive de leur rôle critique dans le maintien de la bonne santé humaine. En fait, notre microbiote – l’ensemble des organismes commensaux qui vivent en nous et sur nous – contribue à pratiquement toutes les facettes de la physiologie hôte, depuis l’ontogénèse du système immunitaire en passant par les fonctions neurologiques jusqu’au métabolisme. Bien que les détails spécifiques des interactions entre le microbiote et son hôte soient encore à élucider pour la plupart des maladies, les rapprochements d’échantillons cliniques avec des modèles animaux de maladies ont apporté des éclaircissements clés. Cet article présente un exposé général de ce qu’est le microbiote, met en lumière quelques exemples sur la manière dont le microbiote a un impact sur certaines maladies du système nerveux central, et fournit une perspective sur la façon dont ces découvertes pourraient se traduire cliniquement.</p>
</trans-abstract>
<kwd-group>
<kwd>
<italic>microbiota</italic>
</kwd>
<kwd>
<italic>clinical translation</italic>
</kwd>
<kwd>
<italic>gut–brain axis</italic>
</kwd>
<kwd>
<italic>neurological disease</italic>
</kwd>
<kwd>
<italic>commensal bacteria</italic>
</kwd>
<kwd>
<italic>immunomodulation</italic>
</kwd>
<kwd>
<italic>microbial metabolism</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>Introduction </title>
<p>
The pioneers of modern microbiology—the likes of Robert Koch and Louis
Pasteur, among others—focused on the idea that host–microbe interactions were
antagonistic in nature, with the host immune system living in a constant struggle
against the myriad microorganisms it encounters on a daily basis. This concept of the
“germ theory” formed the basis of what became the <italic>leitmotif</italic>
of 20th-century microbiology research: a molecular dissection of how
pathogenic microbes cause disease. Although there has always been a small group of
researchers who thought that commensal organisms were similarly important to study, <sup><xref ref-type="bibr" rid="ref1">1</xref></sup>
research into how the microbiota—the collection of all the bacteria,
viruses, fungi, and Archaea that colonize humans—impacts human health really only began
to flourish at the beginning of the 21st century. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
, <sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
Aimed at a better understanding of this relationship, myriad studies
during the past decade have begun to catalogue the microbiota at various body sites and
in a multitude of disease conditions. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
- <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>
Diseases in virtually every organ system have been associated with changes
in the microbiota. Indeed, the microbiota has been linked to intestinal disorders,
disturbances in metabolic function, autoimmune diseases, and psychiatric conditions, and
has been shown to influence susceptibility to infection and the efficacy of
pharmaceutical therapies. Knowledge of the specific mechanism(s) underlying most of
these microbe–disease associations is lacking; it remains unclear whether the
disease-associated alterations in the microbiota represent mere biomarkers of disease, a
causal relationship, or a combination of the two. Although cause-and-effect
relationships are still being elucidated for many diseases, it is clear that humans
coexist in an intricate relationship with commensal organisms. Instead of waging a
continual battle with each other, the host–microbiota relationship reflects a carefully
negotiated state of <italic>détente</italic>
in which each side requires the other. Although this host–commensal
relationship impacts numerous diseases across all organ systems, this review will more
specifically describe some exemplar data of how the microbiome affects diseases of the
central nervous system (CNS) and provide some thoughts on how these findings can be
translated into a novel class of therapeutics.  </p>
</sec>
<sec>
<title>Overview of the microbiota </title>
<p>
There are more than 10 000 different bacterial species present in the
collective human microbiota; the intestines alone contain more than 1000 species. <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
At any given time, the body of any given individual harbors 500 to 1000
bacterial species, <sup><xref ref-type="bibr" rid="ref8">8</xref></sup>
with 100 to 200 bacterial species in the gut alone. <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
The Human Microbiome Project, a seminal study that catalogued the
microbiome in 15 to 18 anatomic sites in ~250 healthy American adults, found that the
composition of the microbiota differs by body site, there exists tremendous
interindividual variation, and the microbial gene content is fairly conserved
irrespective of the body site or individual. <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>
In fact, the effect of the anatomic site on microbial composition is far
greater than the effect of heterogeneity between individuals (ie, all samples from a
given body region [eg, skin] were more similar to each other than they were to samples
from a different body region [eg, stool], even in the same individual). <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>
Taken together, these findings highlight the remarkable personalization of
the human microbiome. While the human genome is typically &gt;99.5% identical in
different people, <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>
the microbiota of two individuals may not overlap at all.  </p>
<p>
In addition to the tremendous diversity contained within the human
microbiome, it is notable that the number of organisms in the microbiota outnumber human
cells in the body by ≥10-fold <sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
- <sup><xref ref-type="bibr" rid="ref13">13</xref></sup>
and that the collective set of genes contained within the microbiota (the
<italic>microbiome</italic>
) is at least 100 times larger than the human genome. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
, <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
Given this numerical superiority of microbes, it is perhaps not surprising
that they are critical for many elements of human physiology. For example, commensal
microbes process nutrients needed by the host, contribute to proper development of the
intestine, provide colonization resistance to many pathogenic organisms, and foster
maturation of the immune system. <sup><xref ref-type="bibr" rid="ref12">12</xref></sup>
, <sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
- <sup><xref ref-type="bibr" rid="ref18">18</xref></sup>
Although the intestines harbor the largest number and diversity of
organisms, microbial effects—often linked to bacteria present in the gut—can be found in
distant sites throughout the body, such as the bone marrow, lungs, and CNS. It is not
clear yet how the gut microbiota communicates with these remote anatomic sites—ie,
whether communication takes place via bacterial metabolites that travel in the
bloodstream, via migration of whole organisms to the target site, or, in the case of the
CNS, via feedback through the vagus nerve.  </p>
<p>
Identification of the factors that influence the microbiota’s composition
is critical to an understanding of what leads to and controls intra- and interindividual
variation in microbial composition and potential disease phenotypes. Some studies have
demonstrated that host genetics have a small but statistically significant effect on the
microbiota’s composition, <sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
- <sup><xref ref-type="bibr" rid="ref21">21</xref></sup>
but there is some controversy over this finding. <sup><xref ref-type="bibr" rid="ref22">22</xref></sup>
, <sup><xref ref-type="bibr" rid="ref23">23</xref></sup>
Moreover, the microbiota changes with age, with pronounced changes
apparent particularly in early infancy and in the elderly. <sup><xref ref-type="bibr" rid="ref24">24</xref></sup>
, <sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
In addition to these factors which are difficult to control, an
individual’s specific microbial configuration is quickly altered in response to subtle
changes in the microenvironments in which the bacteria reside. On a day-to-day basis,
these changes usually reflect alterations in the relative abundance of the various
microbes. However, some exposures have a greater effect on the microbiota and can shift
the microbial population to a new equilibrium via the loss of specific species and/or
the acquisition of others; this new microbial equilibrium can be associated with either
health or a disease state. Diet is perhaps one of the largest drivers of the intestinal
microbiota as it provides nutrients needed not only by our own cells but also by the
microbes living in the alimentary tract. <sup><xref ref-type="bibr" rid="ref26">26</xref></sup>
, <sup><xref ref-type="bibr" rid="ref27">27</xref></sup>
Other factors that can alter the microbiota in a dynamic manner include
lifestyle choices (eg, choice of household members, presence of pets, living in a rural
or urban setting, country of residence) and circadian rhythms. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
, <sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
Furthermore, virtually all drugs have the capacity to change the
microbiota by altering the chemical landscape in which the microorganisms live (eg,
statins, bile acid sequestrants), modulating the host’s ability to recognize and react
to microbes (eg, immunosuppressants), and/or directly interfering with the microbiota’s
constituents (eg, antibiotics). <sup><xref ref-type="bibr" rid="ref29">29</xref></sup>
- <sup><xref ref-type="bibr" rid="ref32">32</xref></sup>
While it is clear that the microbiota can be altered through these various
mechanisms, it is not yet clear whether these changes are biologically significant.  </p>
</sec>
<sec>
<title>The case for the gut–brain axis </title>
<p>
Although numerous studies have associated the microbiota with a panoply of
neurological conditions, the link between microbes and CNS disease predates the more
recent interest in the microbiota. For example, Hippocrates thought that “madness”
resulted from the imbalance of four bodily humors that could be rebalanced by special
diets and purgatives, both of which are now recognized to affect the microbiota.
Physicians caring for King George III, who alternated between bouts of confusion and
angry outbursts, would often examine his stool for insights into the underlying cause of
his abnormal behaviors. In fact, many notable British physicians in the 18th century
thought that the gastrointestinal system, which was known at that time to have its own
nervous system, was central to emotional stability. <sup><xref ref-type="bibr" rid="ref33">33</xref></sup>
In the early to mid-20th century, neurosyphilis and schizophrenia were
treated with “fever therapy” by intentionally infecting patients with <italic>Plasmodium
falciparum</italic>
, the causative agent of malaria <sup><xref ref-type="bibr" rid="ref34">34</xref></sup>
; although this example does not involve the gut microbiota per se, it
provides additional evidence for links between microbes and neurologic function.  </p>
<p>
In more recent years, there have been a barrage of cross-sectional
case–control studies that have associated the gut microbiota with virtually every
neurologic and psychiatric condition imaginable. The issue is that most of these studies
simply provide a descriptive account of the microbiota in patients as compared with
controls, with little or no insight into whether the microbiota is casually related to
disease or whether there exist biological mechanisms that may link microbes with the
phenotype. Fortunately, there are a growing number of studies that combine human data
with animal studies to tease out some of these more complicated relationships, some
examples of which are provided below. In general, the gut and its microbial constituents
are inextricably linked with the central nervous system via regulation of metabolic
processes, connection via nerves, and education of the immune system.  </p>
</sec>
<sec>
<title>Microbial regulation of metabolites </title>
<p>
It is increasingly recognized that microbial metabolism has pervasive
effects on host physiology, and its role in diseases of the central nervous system is no
different. For example, modern medicine has used the ketogenic diet to treat seizures
for over a century. <sup><xref ref-type="bibr" rid="ref35">35</xref></sup>
The underlying mechanism by which it works remained elusive until
investigators recently used a mouse model of seizures to demonstrate that the microbiota
is required for the protective effects of the ketogenic diet. <sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
Moreover, they found that <italic>Akkermansia muciniphila</italic>
and <italic>Parabacteroides merdae</italic>
were more abundant in mice fed a ketogenic diet, and that these bacteria
were sufficient to protect mice fed a normal diet against seizures, likely through the
ability of <italic>P. merdae </italic>
to decrease enteric g-glutamylation which results in increased levels of
hippocampal g-aminobutyric acid (GABA) and glutamate. <sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
Commensal bacteria can also affect host production of other key
neurotransmitters. Serotonin is critically important for a number of neurological and
neuropsychiatric conditions, and it has been known for some time that ~90% of the body’s
serotonin is produced by intestinal enterochromaffin cells, with only ~5% produced in
the brain. <sup><xref ref-type="bibr" rid="ref37">37</xref></sup>
Serotonin production in the colon is regulated by spore-forming bacteria,
which produce specific metabolites that are sensed by enterochromaffin cells. <sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
These enterochromaffin cells then increase expression of tryptophan
hydroxylase 1 (Tph1), which results in increased serotonin biosynthesis and secretion,
both luminally and basolaterally. <sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
Although it is not yet clear whether microbiota-regulated intestinal
serotonin production influences neurological diseases, the microbiota also affects
hippocampal levels of serotonin through unclear mechanisms. <sup><xref ref-type="bibr" rid="ref39">39</xref></sup>
It is tempting to speculate that these two processes are linked in some
way. Beyond affecting the levels of neurotransmitters, some bacterial metabolites can
directly cross the blood–brain barrier and directly affect brain physiology. For
example, the gut microbiota is necessary to metabolize dietary tryptophan. These
metabolites enter the brain where they control microglial activation, TGFa and VEGF-B
production, and transcriptional responses of astrocytes, which together regulate
pathogenesis of multiple sclerosis. <sup><xref ref-type="bibr" rid="ref40">40</xref></sup>
In addition to directly modulating metabolite levels, the microbiota also
plays a key role in maintaining the integrity of the intestinal epithelial layer,
defects in which can cause alterations in systemic levels of metabolites. In a murine
model of autism, treatment of animals with <italic>Bacteroides fragilis</italic>
was able to normalize the barrier integrity and thereby restore levels of
autism-induced abnormalities in serum metabolites. <sup><xref ref-type="bibr" rid="ref41">41</xref></sup>
Thus, the intestinal microbiota is able to directly and indirectly affect
metabolite levels that influence host physiology.  </p>
</sec>
<sec>
<title>Gut-CNS signaling </title>
<p>
The intestines have their own enteric nervous system (ENS), which—with
greater than 100 million neurons—has more neurons that all other peripheral ganglia
combined and at least as many as the spinal cord. <sup><xref ref-type="bibr" rid="ref42">42</xref></sup>
Therefore, it is perhaps not surprising that many neurologic conditions
(eg, Parkinson’s disease, autism, amyotrophic lateral sclerosis) have gastrointestinal
symptoms that often precede the onset of CNS symptoms. While the vagus nerve connects
the CNS and ENS, it should be noted that ~90% of the vagal fibers are afferent in
nature, a finding that suggests there are more signals going from the intestines to the
brain than vice versa. <sup><xref ref-type="bibr" rid="ref43">43</xref></sup>
, <sup><xref ref-type="bibr" rid="ref44">44</xref></sup>
Indeed, vagal nerve stimulation, which mimics signaling from the
intestines to the brain, is approved to treat refractory epilepsy and depression, and it
is being evaluated as a treatment for a number of other neuropsychiatric conditions.
However, the endogenous signals sent via the vagus nerve—and the mechanism by which they
are transduced—have remained enigmatic.  </p>
<p>
It was previously thought that gut stimuli are sensed by the brain via the
passive release of hormones. Enteroendocrine cells, which are rare sensory cells in the
intestinal epithelium, detect nutrients in the intestinal lumen and secrete slow-acting
peptide hormones, such as cholecystokinin and peptide YY, that stimulate neurons
throughout the gut and the brain on the time scale of minutes. However, infusion of
sucrose into the gut-induced vagus nerve activation in an enteroendocrine cell-dependent
manner on a time scale of milliseconds, suggesting that this interaction was more
typical of synaptic transmission than the slow nature of neuropeptide signaling. <sup><xref ref-type="bibr" rid="ref45">45</xref></sup>
Further studies revealed that enteroendocrine cells synapse with vagal
sensory neurons, which they activate through the release of glutamate. <sup><xref ref-type="bibr" rid="ref45">45</xref></sup>
Conceptually, this finding is similar to an earlier report that
serotonergic enterochromaffin cells, a specific type of enteroendocrine cell, synapse
with and modulate primary afferent nerve fibers. <sup><xref ref-type="bibr" rid="ref46">46</xref></sup>
Given that these enteroendocrine cells express toll-like receptors,
activation of which results in neuropeptide release, <sup><xref ref-type="bibr" rid="ref47">47</xref></sup>
it is possible that these enteroendocrine cells also detect the gut
microbiota and signal microbial changes to the brain. These studies lay the foundation
for the molecular mechanisms underlying the gut–brain axis, though it remains to be seen
which physiological processes require gut–brain signaling that occurs on the order of
milliseconds.  </p>
</sec>
<sec>
<title>Microbiome-induced immunomodulation </title>
<p>
The intestines represent the largest immune organ, and the gut microbiota
is vital for inducing maturation of the immune system. Immune cells educated in the gut
traffic throughout the body, including within the CNS, and can influence disease
pathogenesis at these remote sites. <sup><xref ref-type="bibr" rid="ref48">48</xref></sup>
, <sup><xref ref-type="bibr" rid="ref49">49</xref></sup>
Multiple sclerosis is the best studied neurological disease that
exemplifies this particular gut–brain connection. Several studies have noted alterations
in the microbiome of patients with multiple sclerosis, <sup><xref ref-type="bibr" rid="ref50">50</xref></sup>
, <sup><xref ref-type="bibr" rid="ref51">51</xref></sup>
findings that suggest that the gut microbiome may be linked to disease
pathogenesis and which have prompted interventional clinical trials. <sup><xref ref-type="bibr" rid="ref52">52</xref></sup>
, <sup><xref ref-type="bibr" rid="ref53">53</xref></sup>
Using a murine model of multiple sclerosis, oral administration of
<italic>Bacteroides fragilis</italic>
protected mice from disease. <sup><xref ref-type="bibr" rid="ref54">54</xref></sup>
Strikingly, treatment with just the <italic>B. fragilis</italic>
capsular polysaccharide (polysaccharide A, PSA) either before (ie,
prophylactically) or after (ie, treatment) the onset of inflammation was sufficient to
protect mice. <sup><xref ref-type="bibr" rid="ref54">54</xref></sup>
, <sup><xref ref-type="bibr" rid="ref55">55</xref></sup>
Notably, PSA induces accumulation of interleukin 10-producing regulatory T
cells in the cervical lymph node even though PSA was administered orally. Given that
CD11chighCD103+ dendritic cells, which are typically restrained to the intestines, also
accumulated in the cervical lymph node, <sup><xref ref-type="bibr" rid="ref55">55</xref></sup>
it is thought that PSA is taken up by dendritic cells in the intestine and
trafficked to the cervical lymph node, where they induce differentiation of naïve T
cells into regulatory T cells. Intriguingly, this dendritic cell migration only occurred
in the setting of inflammation, potentially due to inflammation-associated alterations
in vascular permeability or the cytokine milieu. In contrast to the protective effects
seen with <italic>B. fragilis</italic>
PSA, other intestinal microbes exacerbate disease. For instance,
intestinal colonization with segmented filamentous bacteria not only induces
IL-17-producing T cells (Th17) in the gut but also in the CNS, where they promote
disease in a mouse model of multiple sclerosis. <sup><xref ref-type="bibr" rid="ref56">56</xref></sup>
, <sup><xref ref-type="bibr" rid="ref57">57</xref></sup>
Taken together, these studies highlight that microbially induced changes
in the intestinal immune system can have systemic effects that cross the blood–brain
barrier and affect progression of neurological diseases.  </p>
</sec>
<sec>
<title>Translating microbiome science to the clinic </title>
<p>
The numerous microbiome–disease associations identified thus far have
generated a great deal of hope that understanding the relevant microbe–host interactions
will open the door to unlimited therapeutic applications. Microbiome-based therapies
offer several potential benefits. Patients often view such treatment as more “natural”
than conventional drug therapy and are therefore more likely to comply with it.
Biologically, microbiome-based therapies are more likely to address one of the root
causes of disease (microbial dysbiosis) rather than simply affecting the downstream
sequelae. Finally, a given microbiome-based therapy may serve as a “polypill” that is
effective against several different diseases stemming from similar microbial changes.
Despite tremendous interest in therapeutically exploiting the microbiome, there have
thus far been few clinical successes along these lines.  </p>
<p>
The most successful therapeutic application of microbiome science has been
the use of fecal microbiota transplantation (FMT), particularly for recurrent
<italic>Clostridiodes difficile</italic>
infections (CDI). FMT involves “transplanting” stool from a healthy
individual to a diseased patient, with the idea that the “healthy” microbiota will
correct whatever derangement may exist in the ill patient and therefore will alleviate
symptoms. Fundamentally, this notion is agnostic as to the specific microbial dysbiosis
and holds that any healthy microbiota will be curative. The idea of FMT dates back to at
least the fourth century, when traditional Chinese doctors used a “yellow soup” (fresh
human fecal suspension) to successfully treat food poisoning and severe diarrhea. <sup><xref ref-type="bibr" rid="ref58">58</xref></sup>
The continued use of FMT through the centuries for the treatment of
diarrheal illnesses in both humans and animals, along with the growing appreciation in
recent years of the importance of the microbiota, laid the groundwork for using FMT to
treat CDI. Since the first major prospective trial assessing FMT for recurrent CDI in
2013, <sup><xref ref-type="bibr" rid="ref59">59</xref></sup>
most of the numerous studies of FMT for CDI have demonstrated remarkable
efficacy, with an average clinical cure rate of ≥85%. <sup><xref ref-type="bibr" rid="ref60">60</xref></sup>
, <sup><xref ref-type="bibr" rid="ref61">61</xref></sup>
The donor stool can be fresh or frozen (use of the latter allows
biobanking of samples from a limited number of prescreened donors) and can be
administered via nasogastric tube, nasoduodenal tube, colonoscopy, enema, or oral
capsules; the cure rate is slightly higher with lower gastrointestinal administration
than with upper gastrointestinal treatment. <sup><xref ref-type="bibr" rid="ref61">61</xref></sup>
The optimal screening, preparation, and concentration of infused donor
stool have not yet been determined. The most common adverse effects of FMT include
altered gastrointestinal motility (with constipation or diarrhea), abdominal cramps, and
bloating, all of which are generally transient and resolve within 48 h. <sup><xref ref-type="bibr" rid="ref60">60</xref></sup>
, <sup><xref ref-type="bibr" rid="ref61">61</xref></sup>
At least 80 immunosuppressed patients have undergone FMT with no serious
adverse events noted during 3 months of follow-up. <sup><xref ref-type="bibr" rid="ref61">61</xref></sup>
  </p>
<p>
The successful use and the favorable short-term safety profile of FMT for
CDI have led to its expanded application for other indications. At the end of 2018, 195
active trials (listed at ClinicalTrials.gov) were investigating the efficacy of FMT for
a range of diseases, including CDI, inflammatory bowel disease (IBD; ulcerative colitis,
and Crohn’s disease), obesity, eradication of multidrug-resistant organisms, anxiety and
depression, cirrhosis, and type 2 diabetes. The few published studies regarding
indications other than CDI have generally included small sample sizes and have offered
mixed results. <sup><xref ref-type="bibr" rid="ref62">62</xref></sup>
- <sup><xref ref-type="bibr" rid="ref64">64</xref></sup>
In contrast to the successes in CDI, the results have been more varied for
patients with IBD, <sup><xref ref-type="bibr" rid="ref65">65</xref></sup>
which is perhaps the second-best-studied indication. It is not clear
whether these discrepancies are due to heterogeneity in recipients (eg, in terms of
underlying disease mechanisms or endogenous microbiotas), the donor material, and/or the
logistical details of FMT administration (eg, route, frequency, dose).  </p>
<p>
Although FMT offers an important proof of concept that microbiome-based
therapies can be effective, treatment is difficult to standardize across large
populations because of variability among stool donors and among the endogenous
microbiotas of recipients. In addition, FMT is fraught with safety concerns, and its
mechanism(s) of action are unclear. FMT likely represents the first generation of
microbiome-based therapies; subsequent generations will include the use of more refined
bacterial cocktails, single strains of bacteria, or bacterial metabolites as the
therapeutic intervention. The field of probiotics has a complicated history: many
different strains have been tested against a multitude of diseases. Several
meta-analyses have combined results across bacterial strains and/or disease indications
and have generally concluded that the data are not yet convincing enough to support the
use of the tested regimens. <sup><xref ref-type="bibr" rid="ref65">65</xref></sup>
- <sup><xref ref-type="bibr" rid="ref68">68</xref></sup>
It should be noted that the tested organisms have been chosen mainly on
the basis of their presumed safety profile rather than in light of a plausible
biological link to disease. The hope is that more focused, mechanistic microbiome
studies will identify specific commensal organisms—and their underlying mechanisms of
action—that are involved in disease pathogenesis and that will serve as the basis for
the next wave of rationally chosen probiotics, a few of which are currently in clinical
trials. The main hurdle in this endeavor has been identifying specific microbes that are
causally related to protection from disease. <sup><xref ref-type="bibr" rid="ref69">69</xref></sup>
, <sup><xref ref-type="bibr" rid="ref70">70</xref></sup>
To avoid the issue associated with many over-the-counter probiotic and
nutritional supplements being adulterated (ie, contain undisclosed components and/or do
not contain the ingredients claimed), <sup><xref ref-type="bibr" rid="ref71">71</xref></sup>
, <sup><xref ref-type="bibr" rid="ref72">72</xref></sup>
the hope is that the these next-generation microbiome-based therapies will
go through the normal regulatory approval processes to ensure patient safety.  </p>
</sec>
<sec>
<title>Perspectives </title>
<p>
Animal studies have made clear that microbiome-based therapeutics are a
viable and effective option for treating a range of diseases, and the early examples in
clinical trials—which have mostly concentrated on application of FMT at this point—have
yielded promising results. However, our understanding is still in its infancy of what is
an “optimal” microbiome profile and how to specifically shift from one microbial state
to another. The ability to generate incredible amounts of data through high-throughput
sequencing and high-dimensional metabolite profiling has so far outpaced knowledge in
how to integrate these datasets, yet efforts are ongoing to understand how to do so. As
we develop a better grasp of how microbes (either individually or collectively) and
microbial products impact host physiology, these findings will be able to be translated
into next-generation microbiome-based therapeutics that have the potential to alter the
treatment landscape of many neurologic and psychiatric conditions.  </p>
</sec>
</body>
<back>
<ack>
<p>NKS receives support as a Whitehead Scholar and a Translating Duke Health Scholar as
well as from NIH grant K08 AI108690. The author denies any relevant conflicts of
interest.</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kendall</surname>
<given-names>AI.</given-names>
</name>
</person-group>
<article-title>Some observations on the study of the intestinal
bacteria.</article-title>
<source/>
<italic>J Biol Chem.</italic>
<year>1909</year>
<volume>6</volume>
<fpage>499</fpage>
<lpage>507</lpage>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Blaser</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Caporaso</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Jansson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Current understanding of the human microbiome.</article-title>
<source/>
<italic>Nat Med.</italic>
<year>2018</year>
<volume>24</volume>
<issue>4</issue>
<fpage>392</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">29634682</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surana</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>DL.</given-names>
</name>
</person-group>
<article-title>Deciphering the tete-a-tete between the microbiota and the immune
system.</article-title>
<source/>
<italic>J Clin Invest.</italic>
<year>2014</year>
<volume>124</volume>
<issue>10</issue>
<fpage>4197</fpage>
<lpage>4203</lpage>
<pub-id pub-id-type="pmid">25036709</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Microbiome-wide association studies link dynamic microbial consortia
to disease.</article-title>
<source/>
<italic>Nature.</italic>
<year>2016</year>
<volume>535</volume>
<issue>7610</issue>
<fpage>94</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">27383984</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Littman</surname>
<given-names>DR.</given-names>
</name>
</person-group>
<article-title>The microbiome in infectious disease and inflammation.</article-title>
<source/>
<italic>Annu Rev Immunol.</italic>
<year>2012</year>
<volume>30</volume>
<fpage>759</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="pmid">22224764</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>The human intestinal microbiome in health and disease.</article-title>
<source/>
<italic>N Engl J Med.</italic>
<year>2016</year>
<volume>375</volume>
<issue>24</issue>
<fpage>2369</fpage>
<lpage>2379</lpage>
<pub-id pub-id-type="pmid">27974040</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Raes</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A human gut microbial gene catalogue established by metagenomic
sequencing.</article-title>
<source/>
<italic>Nature.</italic>
<year>2010</year>
<volume>464</volume>
<issue>7285</issue>
<fpage>59</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">20203603</pub-id>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hamady</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fraser-Liggett</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI.</given-names>
</name>
</person-group>
<article-title>The human microbiome project.</article-title>
<source/>
<italic>Nature.</italic>
<year>2007</year>
<volume>449</volume>
<issue>7164</issue>
<fpage>804</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">17943116</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<article-title>Structure, function and diversity of the healthy human
microbiome.</article-title>
<source/>
<italic>Nature.</italic>
<year>2012</year>
<volume>486</volume>
<issue>7402</issue>
<fpage>207</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">22699609</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genomes Project</surname>
<given-names> C</given-names>
</name>
<name>
<surname>Auton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>LD</given-names>
</name>
</person-group>
<article-title>A global reference for human genetic variation.</article-title>
<source/>
<italic>Nature.</italic>
<year>2015</year>
<volume>526</volume>
<issue>7571</issue>
<fpage>68</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">26432245</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobzhansky</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title></article-title>
<source/>
<italic></italic>
<year>1971</year>
<volume>Vol 1</volume>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luckey</surname>
<given-names>TD.</given-names>
</name>
</person-group>
<article-title>Introduction to intestinal microecology.</article-title>
<source/>
<italic>Am J Clin Nutr.</italic>
<year>1972</year>
<volume>25</volume>
<issue>12</issue>
<fpage>1292</fpage>
<lpage>1294</lpage>
<pub-id pub-id-type="pmid">4639749</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sender</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Milo</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Are we really vastly outnumbered? revisiting the ratio of bacterial to
host cells in humans.</article-title>
<source/>
<italic>Cell.</italic>
<year>2016</year>
<volume>164</volume>
<issue>3</issue>
<fpage>337</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">26824647</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI.</given-names>
</name>
</person-group>
<article-title>Commensal host-bacterial relationships in the gut.</article-title>
<source/>
<italic>Science.</italic>
<year>2001</year>
<volume>292</volume>
<issue>5519</issue>
<fpage>1115</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="pmid">11352068</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Thelin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI.</given-names>
</name>
</person-group>
<article-title>Molecular analysis of commensal host-microbial relationships in the
intestine.</article-title>
<source/>
<italic>Science.</italic>
<year>2001</year>
<volume>291</volume>
<issue>5505</issue>
<fpage>881</fpage>
<lpage>884</lpage>
<pub-id pub-id-type="pmid">11157169</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Yatsunenko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Manary</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Gut microbiomes of Malawian twin pairs discordant for
kwashiorkor.</article-title>
<source/>
<italic>Science.</italic>
<year>2013</year>
<volume>339</volume>
<issue>6119</issue>
<fpage>548</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">23363771</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Waaij</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Berghuis-de Vries</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lekkerkerk van der Wees</surname>
<given-names>JEC.</given-names>
</name>
</person-group>
<article-title>Colonization resistance of the digestive tract in conventional and
antibiotic-treated mice.</article-title>
<source/>
<italic></italic>
<year>1971</year>
<volume>69</volume>
<issue>3</issue>
<fpage>405</fpage>
<lpage>411</lpage>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pamp</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Gut immune maturation depends on colonization with a host-specific
microbiota.</article-title>
<source/>
<italic>Cell.</italic>
<year>2012</year>
<volume>149</volume>
<issue>7</issue>
<fpage>1578</fpage>
<lpage>1593</lpage>
<pub-id pub-id-type="pmid">22726443</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodrich</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Poole</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Human genetics shape the gut microbiome.</article-title>
<source/>
<italic>Cell.</italic>
<year>2014</year>
<volume>159</volume>
<issue>4</issue>
<fpage>789</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="pmid">25417156</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kua</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tanca</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Protective major histocompatibility complex allele prevents type 1
diabetes by shaping the intestinal microbiota early in ontogeny.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>2017</year>
<volume>114</volume>
<issue>36</issue>
<fpage>9671</fpage>
<lpage>9676</lpage>
<pub-id pub-id-type="pmid">28831005</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubinak</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>WZ</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>MHC variation sculpts individualized microbial communities that
control susceptibility to enteric infection.</article-title>
<source/>
<italic>Nature Communications.</italic>
<year>2015</year>
<volume>6</volume>
<fpage>8642</fpage>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothschild</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weissbrod</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Barkan</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Environment dominates over host genetics in shaping human gut
microbiota.</article-title>
<source/>
<italic>Nature.</italic>
<year>2018</year>
<volume>555</volume>
<issue>7695</issue>
<fpage>210</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">29489753</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hamady</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yatsunenko</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A core gut microbiome in obese and lean twins.</article-title>
<source/>
<italic>Nature.</italic>
<year>2009</year>
<volume>457</volume>
<issue>7228</issue>
<fpage>480</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="pmid">19043404</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yatsunenko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Manary</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Human gut microbiome viewed across age and geography.</article-title>
<source/>
<italic>Nature.</italic>
<year>2012</year>
<volume>486</volume>
<issue>7402</issue>
<fpage>222</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="pmid">22699611</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Toole</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>IB.</given-names>
</name>
</person-group>
<article-title>Gut microbiota and aging.</article-title>
<source/>
<italic>Science.</italic>
<year>2015</year>
<volume>350</volume>
<issue>6265</issue>
<fpage>1214</fpage>
<lpage>1215</lpage>
<pub-id pub-id-type="pmid">26785481</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Maurice</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Carmody</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Diet rapidly and reproducibly alters the human gut
microbiome.</article-title>
<source/>
<italic>Nature.</italic>
<year>2014</year>
<volume>505</volume>
<issue>7484</issue>
<fpage>559</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="pmid">24336217</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ridaura</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Faith</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>JI.</given-names>
</name>
</person-group>
<article-title>The effect of diet on the human gut microbiome: a metagenomic analysis
in humanized gnotobiotic mice.</article-title>
<source/>
<italic>Sci Transl Med.</italic>
<year>2009</year>
<volume>1</volume>
<issue>6</issue>
<fpage>6ra14</fpage>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thaiss</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Korem</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Microbiota diurnal rhythmicity programs host transcriptome
oscillations.</article-title>
<source/>
<italic>Cell.</italic>
<year>2016</year>
<volume>167</volume>
<issue>6</issue>
<fpage>1495</fpage>
<lpage>1510</lpage>
<comment>e1412</comment>
<pub-id pub-id-type="pmid">27912059</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dethlefsen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huse</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sogin</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Relman</surname>
<given-names>DA.</given-names>
</name>
</person-group>
<article-title>The pervasive effects of an antibiotic on the human gut microbiota, as
revealed by deep 16S rRNA sequencing.</article-title>
<source/>
<italic>PLoS Biol.</italic>
<year>2008</year>
<volume>6</volume>
<issue>11</issue>
<fpage>e280</fpage>
<pub-id pub-id-type="pmid">19018661</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dethlefsen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Relman</surname>
<given-names>DA.</given-names>
</name>
</person-group>
<article-title>Incomplete recovery and individualized responses of the human distal
gut microbiota to repeated antibiotic perturbation.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>2011</year>
<volume>108</volume>
<issue>suppl 1</issue>
<fpage>S4554</fpage>
<lpage>S4561</lpage>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forslund</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hildebrand</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Disentangling type 2 diabetes and metformin treatment signatures in
the human gut microbiota.</article-title>
<source/>
<italic>Nature.</italic>
<year>2015</year>
<volume>528</volume>
<issue>7581</issue>
<fpage>262</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="pmid">26633628</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pruteanu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Extensive impact of non-antibiotic drugs on human gut
bacteria.</article-title>
<source/>
<italic>Nature.</italic>
<year>2018</year>
<volume>555</volume>
<issue>7698</issue>
<fpage>623</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">29555994</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>The gut-brain axis: historical reflections.</article-title>
<source/>
<italic>Microb Ecol Health Dis.</italic>
<year>2018</year>
<volume>29</volume>
<issue>1</issue>
<fpage>1542921</fpage>
<pub-id pub-id-type="pmid">30425612</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nevin</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>AM.</given-names>
</name>
</person-group>
<article-title>Psychiatric effects of malaria and anti-malarial drugs: historical and
modern perspectives.</article-title>
<source/>
<italic>Malar J.</italic>
<year>2016</year>
<volume>15</volume>
<fpage>332</fpage>
<pub-id pub-id-type="pmid">27335053</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheless</surname>
<given-names>JW.</given-names>
</name>
</person-group>
<article-title>History of the ketogenic diet.</article-title>
<source/>
<italic>Epilepsia.</italic>
<year>2008</year>
<volume>49</volume>
<issue>suppl 8</issue>
<fpage>S3</fpage>
<lpage>S5</lpage>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Vuong</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>QY</given-names>
</name>
<name>
<surname>Nusbaum</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>EY.</given-names>
</name>
</person-group>
<article-title>The gut microbiota mediates the anti-seizure effects of the ketogenic
diet.</article-title>
<source/>
<italic>Cell.</italic>
<year>2018</year>
<volume>173</volume>
<issue>7</issue>
<fpage>1728</fpage>
<lpage>1741</lpage>
<comment>e1713</comment>
<pub-id pub-id-type="pmid">29804833</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershon</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Tack</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The serotonin signaling system: from basic understanding to drug
development for functional GI disorders.</article-title>
<source/>
<italic>Gastroenterology.</italic>
<year>2007</year>
<volume>132</volume>
<issue>1</issue>
<fpage>397</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="pmid">17241888</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yano</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>Indigenous bacteria from the gut microbiota regulate host serotonin
biosynthesis.</article-title>
<source/>
<italic>Cell.</italic>
<year>2015</year>
<volume>161</volume>
<issue>2</issue>
<fpage>264</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">25860609</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grenham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scully</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The microbiome-gut-brain axis during early life regulates the
hippocampal serotonergic system in a sex- dependent manner.</article-title>
<source/>
<italic>Mol Psychiatry.</italic>
<year>2013</year>
<volume>18</volume>
<issue>6</issue>
<fpage>666</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="pmid">22688187</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothhammer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Borucki</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Tjon</surname>
<given-names>EC</given-names>
</name>
</person-group>
<article-title>Microglial control of astrocytes in response to microbial
metabolites.</article-title>
<source/>
<italic>Nature.</italic>
<year>2018</year>
<volume>557</volume>
<issue>7707</issue>
<fpage>724</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="pmid">29769726</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hsien</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Microbiota modulate behavioral and physiological abnormalities
associated with neurodevelopmental disorders.</article-title>
<source/>
<italic>Cell.</italic>
<year>2013</year>
<volume>155</volume>
<issue>7</issue>
<fpage>1451</fpage>
<lpage>1463</lpage>
<pub-id pub-id-type="pmid">24315484</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gershon</surname>
<given-names>MD.</given-names>
</name>
</person-group>
<article-title>The bowel and beyond: the enteric nervous system in neurological
disorders.</article-title>
<source/>
<italic>Nat Rev Gastroenterol Hepatol.</italic>
<year>2016</year>
<volume>13</volume>
<issue>9</issue>
<fpage>517</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">27435372</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsythe</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bienenstock</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kunze</surname>
<given-names>WA.</given-names>
</name>
</person-group>
<article-title>Vagal pathways for microbiome-brain-gut axis
communication.</article-title>
<source/>
<italic>Adv Exp Med Biol.</italic>
<year>2014</year>
<volume>817</volume>
<fpage>115</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">24997031</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furness</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Callaghan</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>HJ.</given-names>
</name>
</person-group>
<article-title>The enteric nervous system and gastrointestinal innervation:
integrated local and central control.</article-title>
<source/>
<italic>Adv Exp Med Biol.</italic>
<year>2014</year>
<volume>817</volume>
<fpage>39</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">24997029</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaelberer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>A gut-brain neural circuit for nutrient sensory
transduction.</article-title>
<source/>
<italic>Science.</italic>
<year>2018</year>
<volume>361</volume>
<issue>6408</issue>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellono</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Bayrer</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Leitch</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>Enterochromaffin cells are gut chemosensors that couple to sensory
neural pathways.</article-title>
<source/>
<italic>Cell.</italic>
<year>2017</year>
<volume>170</volume>
<issue>1</issue>
<fpage>185</fpage>
<lpage>198</lpage>
<comment>e116</comment>
<pub-id pub-id-type="pmid">28648659</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogunovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dave</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Tilstra</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Enteroendocrine cells express functional Toll-like
receptors.</article-title>
<source/>
<italic>Am J Physiol Gastrointest Liver Physiol.</italic>
<year>2007</year>
<volume>292</volume>
<issue>6</issue>
<fpage>G1770</fpage>
<lpage>1783</lpage>
<pub-id pub-id-type="pmid">17395901</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunkel</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>EC.</given-names>
</name>
</person-group>
<article-title>Plasma-cell homing.</article-title>
<source/>
<italic>Nat Rev Immunol.</italic>
<year>2003</year>
<volume>3</volume>
<issue>10</issue>
<fpage>822</fpage>
<lpage>829</lpage>
<pub-id pub-id-type="pmid">14523388</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surana</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>DL.</given-names>
</name>
</person-group>
<article-title>The yin yang of bacterial polysaccharides: lessons learned from B.
fragilis PSA.</article-title>
<source/>
<italic>Immunol Rev.</italic>
<year>2012</year>
<volume>245</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">22168411</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kalari</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis patients have a distinct gut microbiota compared to
healthy controls.</article-title>
<source/>
<italic>Scientific Reports.</italic>
<year>2016</year>
<volume>6</volume>
<fpage>28484</fpage>
<pub-id pub-id-type="pmid">27346372</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jangi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Alterations of the human gut microbiome in multiple
sclerosis.</article-title>
<source/>
<italic>Nature Communications.</italic>
<year>2016</year>
<volume>7</volume>
<fpage>12015</fpage>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tankou</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Regev</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>BC</given-names>
</name>
</person-group>
<article-title>A probiotic modulates the microbiome and immunity in multiple
sclerosis.</article-title>
<source/>
<italic>Ann Neurol.</italic>
<year>2018</year>
<volume>83</volume>
<issue>6</issue>
<fpage>1147</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="pmid">29679417</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voldsgaard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bager</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Garde</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Trichuris suis ova therapy in relapsing multiple sclerosis is safe but
without signals of beneficial effect.</article-title>
<source/>
<italic>Mult Scler.</italic>
<year>2015</year>
<volume>21</volume>
<issue>13</issue>
<fpage>1723</fpage>
<lpage>1729</lpage>
<pub-id pub-id-type="pmid">25698173</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochoa-Reparaz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mielcarz</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ditrio</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Central nervous system demyelinating disease protection by the human
commensal Bacteroides fragilis depends on polysaccharide A
expression.</article-title>
<source/>
<italic>J Immunol.</italic>
<year>2010</year>
<volume>185</volume>
<issue>7</issue>
<fpage>4101</fpage>
<lpage>4108</lpage>
<pub-id pub-id-type="pmid">20817872</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochoa-Reparaz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mielcarz</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>A polysaccharide from the human commensal Bacteroides fragilis
protects against CNS demyelinating disease.</article-title>
<source/>
<italic>Mucosal Immunol.</italic>
<year>2010</year>
<volume>3</volume>
<issue>5</issue>
<fpage>487</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="pmid">20531465</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanov</surname>
<given-names>II</given-names>
</name>
<name>
<surname>Atarashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Manel</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Induction of intestinal Th17 cells by segmented filamentous
bacteria.</article-title>
<source/>
<italic>Cell.</italic>
<year>2009</year>
<volume>139</volume>
<issue>3</issue>
<fpage>485</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="pmid">19836068</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Umesaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>SK.</given-names>
</name>
</person-group>
<article-title>Proinflammatory T-cell responses to gut microbiota promote
experimental autoimmune encephalomyelitis.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>2011</year>
<volume>108 </volume>
<issue>suppl 1</issue>
<fpage>S4615</fpage>
<lpage>S4622</lpage>
</element-citation>
</ref>
<ref id="ref58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>VB.</given-names>
</name>
</person-group>
<article-title>Therapeutic manipulation of the microbiota: past, present, and
considerations for the future.</article-title>
<source/>
<italic>Clin Microbiol Infect.</italic>
<year>2016</year>
<volume>22</volume>
<issue>11</issue>
<fpage>905</fpage>
<lpage>909</lpage>
<pub-id pub-id-type="pmid">27619640</pub-id>
</element-citation>
</ref>
<ref id="ref59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Nood</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vrieze</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nieuwdorp</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Duodenal infusion of donor feces for recurrent Clostridium
difficile.</article-title>
<source/>
<italic>N Engl J Med.</italic>
<year>2013</year>
<volume>368</volume>
<issue>5</issue>
<fpage>407</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">23323867</pub-id>
</element-citation>
</ref>
<ref id="ref60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ianiro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burisch</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Efficacy of different faecal microbiota transplantation protocols for
Clostridium difficile infection: A systematic review and
meta-analysis.</article-title>
<source/>
<italic>United European Gastroenterol J.</italic>
<year>2018</year>
<volume>6</volume>
<issue>8</issue>
<fpage>1232</fpage>
<lpage>1244</lpage>
</element-citation>
</ref>
<ref id="ref61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quraishi</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Widlak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bhala</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Systematic review with meta-analysis: the efficacy of faecal
microbiota transplantation for the treatment of recurrent and refractory
Clostridium difficile infection.</article-title>
<source/>
<italic>Aliment Pharmacol Ther.</italic>
<year>2017</year>
<volume>46</volume>
<issue>5</issue>
<fpage>479</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="pmid">28707337</pub-id>
</element-citation>
</ref>
<ref id="ref62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halkjaer</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>BZS</given-names>
</name>
</person-group>
<article-title>Faecal microbiota transplantation alters gut microbiota in patients
with irritable bowel syndrome: results from a randomised, double-blind
placebo-controlled study.</article-title>
<source/>
<italic>Gut.</italic>
<year>2018</year>
<volume>67</volume>
<issue>12</issue>
<fpage>2107</fpage>
<lpage>2115</lpage>
<pub-id pub-id-type="pmid">29980607</pub-id>
</element-citation>
</ref>
<ref id="ref63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Microbiota transfer therapy alters gut ecosystem and improves
gastrointestinal and autism symptoms: an open-label study.</article-title>
<source/>
<italic>Microbiome.</italic>
<year>2017</year>
<volume>5</volume>
<issue>1</issue>
<fpage>10</fpage>
<pub-id pub-id-type="pmid">28122648</pub-id>
</element-citation>
</ref>
<ref id="ref64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Geerlings</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation against intestinal colonization by
extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of
principle study.</article-title>
<source/>
<italic>BMC Res Notes.</italic>
<year>2018</year>
<volume>11</volume>
<issue>1</issue>
<fpage>190</fpage>
<pub-id pub-id-type="pmid">29566738</pub-id>
</element-citation>
</ref>
<ref id="ref65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imdad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Tanner-Smith</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Fecal transplantation for treatment of inflammatory bowel
disease.</article-title>
<source/>
<italic>Cochrane Database Syst Rev.</italic>
<year>2018</year>
<volume>11</volume>
<fpage>CD012774</fpage>
<pub-id pub-id-type="pmid">30480772</pub-id>
</element-citation>
</ref>
<ref id="ref66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Riordan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>AC.</given-names>
</name>
</person-group>
<article-title>Probiotics for people with hepatic encephalopathy.</article-title>
<source/>
<italic>Cochrane Database Syst Rev.</italic>
<year>2017</year>
<volume>2</volume>
<fpage>CD008716</fpage>
<pub-id pub-id-type="pmid">28230908</pub-id>
</element-citation>
</ref>
<ref id="ref67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grev</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soll</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Maternal probiotic supplementation for prevention of morbidity and
mortality in preterm infants.</article-title>
<source/>
<italic>Cochrane Database Syst Rev.</italic>
<year>2018</year>
<volume>12</volume>
<fpage>CD012519</fpage>
<pub-id pub-id-type="pmid">30548483</pub-id>
</element-citation>
</ref>
<ref id="ref68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwenger</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Tejani</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Loewen</surname>
<given-names>PS.</given-names>
</name>
</person-group>
<article-title>Probiotics for preventing urinary tract infections in adults and
children.</article-title>
<source/>
<italic>Cochrane Database Syst Rev.</italic>
<year>2015</year>
<volume>12</volume>
<fpage>CD008772</fpage>
</element-citation>
</ref>
<ref id="ref69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischbach</surname>
<given-names>MA.</given-names>
</name>
</person-group>
<article-title>Microbiome: focus on causation and mechanism.</article-title>
<source/>
<italic>Cell.</italic>
<year>2018</year>
<volume>174</volume>
<issue>4</issue>
<fpage>785</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="pmid">30096310</pub-id>
</element-citation>
</ref>
<ref id="ref70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surana</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>DL.</given-names>
</name>
</person-group>
<article-title>Moving beyond microbiome-wide associations to causal microbe
identification.</article-title>
<source/>
<italic>Nature.</italic>
<year>2017</year>
<volume>552</volume>
<issue>7684</issue>
<fpage>244</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="pmid">29211710</pub-id>
</element-citation>
</ref>
<ref id="ref71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>PA.</given-names>
</name>
</person-group>
<article-title>Probiotic safety-no guarantees.</article-title>
<source/>
<italic>JAMA Intern Med.</italic>
<year>2018</year>
<volume>178</volume>
<issue>12</issue>
<fpage>1577</fpage>
<lpage>1578</lpage>
<pub-id pub-id-type="pmid">30242393</pub-id>
</element-citation>
</ref>
<ref id="ref72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>PA.</given-names>
</name>
</person-group>
<article-title>The FDA and adulterated supplements-dereliction of
duty.</article-title>
<source/>
<italic>JAMA Netw Open.</italic>
<year>2018</year>
<volume>1</volume>
<issue>6</issue>
<fpage>e183329</fpage>
<pub-id pub-id-type="pmid">30646231</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>